PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för fezolinetant. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

36 hits

Bibliografisk träff 2023-03-09

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.

Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD.

Obstet Gynecol · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1097/aog.0000000000005114

Bibliografisk träff 2021-08-01

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.

Fraser GL, Obermayer-Pietsch B, Laven J, Griesinger G, Pintiaux A, Timmerman D, Fauser BCJM, Lademacher C, Combalbert J, Hoveyda HR, Ramael S.

J Clin Endocrinol Metab · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1210/clinem/dgab320

Bibliografisk träff 2021-07-12

Fezolinetant in the treatment of vasomotor symptoms associated with menopause.

Depypere H, Lademacher C, Siddiqui E, Fraser GL.

Expert Opin Investig Drugs · review; journal article · DOI 10.1080/13543784.2021.1893305

Bibliografisk träff 2021-05-25

Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.

Tahara A, Takamatsu H, Ohtake A, Tanaka-Amino K, Kaku S.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2021.174207

Bibliografisk träff 2020-12-01

Fezolinetant findings can fuel future instrumentation inquiries.

Carpenter JS.

Menopause · comment; journal article · DOI 10.1097/gme.0000000000001648

Bibliografisk träff 2019-12-01

Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.

Depypere H, Timmerman D, Donders G, Sieprath P, Ramael S, Combalbert J, Hoveyda HR, Fraser GL.

J Clin Endocrinol Metab · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1210/jc.2019-00677